Helsinki improved transcranial magnetic stimulation for depressio
- Conditions
- Major depressive disorderMental and Behavioural Disorders
- Registration Number
- ISRCTN46722730
- Lead Sponsor
- Hospital District of Helsinki and Uusimaa
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Ongoing
- Sex
- All
- Target Recruitment
- 80
1. Diagnosis of major depressive disorder (DSM-IV) as the principal diagnosis with Patient Health Questionnaire-9 score >14
2. Inability to tolerate antidepressant medication or unresponsiveness to minimum of 2 months trial with adequate dose of antidepressant
3. No change in antidepressive medication in four weeks prior to treatment
1. Previous rTMS treatment
2. Borderline personality features exceeding 7 points in McLean Screening Instrument for Borderline Personality Disorder, or other somatic or psychiatric conditions that likely interfere with recovery from depression with TMS (an unstable medical illness, substantial neurological illness, chronic pain, psychotic disorder or current psychotic symptoms, substance abuse or dependency within last 3 months, >2 mg lorazepine equivalents benzodiazepine use daily or any anticonvulsant, or lifetime history of non-response to an adequate course—ie, a minimum of eight treatments—of electroconvulsive therapy)
3. Patients with safety risks including active suicidality, pregnancy, magnetic metal or leads in the upper body, or history of seizures
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Current primary outcome measure as of 03/06/2021: <br><br>Montgomery Åsberg Depression Rating Scale (MADRS) rated by research team psychiatrist before, and within two weeks after treatment<br><br>_____<br><br>Previous primary outcome measure:<br><br>Montgomery Åsberg Depression Rating Scale (MADRS) rated by research team psychiatrist before, and within one week after treatment
- Secondary Outcome Measures
Name Time Method